rs1336353571
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PP3_ModerateBS2
The ENST00000324631.13(CACNB2):c.1276G>A(p.Ala426Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000566 in 1,590,262 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A426V) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000324631.13 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CACNB2 | NM_201596.3 | c.1276G>A | p.Ala426Thr | missense_variant | 12/14 | ENST00000324631.13 | NP_963890.2 | |
CACNB2 | NM_201590.3 | c.1114G>A | p.Ala372Thr | missense_variant | 11/13 | ENST00000377329.10 | NP_963884.2 | |
LOC124902386 | XR_007062076.1 | n.83+3024C>T | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNB2 | ENST00000324631.13 | c.1276G>A | p.Ala426Thr | missense_variant | 12/14 | 1 | NM_201596.3 | ENSP00000320025 | ||
CACNB2 | ENST00000377329.10 | c.1114G>A | p.Ala372Thr | missense_variant | 11/13 | 1 | NM_201590.3 | ENSP00000366546 | ||
ENST00000425669.1 | n.482+3024C>T | intron_variant, non_coding_transcript_variant | 1 |
Frequencies
GnomAD3 genomes AF: 0.00000676 AC: 1AN: 148028Hom.: 0 Cov.: 30
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251414Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135886
GnomAD4 exome AF: 0.00000555 AC: 8AN: 1442234Hom.: 0 Cov.: 29 AF XY: 0.00000279 AC XY: 2AN XY: 717780
GnomAD4 genome AF: 0.00000676 AC: 1AN: 148028Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 71952
ClinVar
Submissions by phenotype
Brugada syndrome 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 23, 2021 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with CACNB2-related conditions. ClinVar contains an entry for this variant (Variation ID: 427977). This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with threonine at codon 372 of the CACNB2 protein (p.Ala372Thr). The alanine residue is highly conserved and there is a small physicochemical difference between alanine and threonine. - |
Primary dilated cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Human Genetics, University of Leuven | Apr 30, 2017 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 04, 2019 | The p.A372T variant (also known as c.1114G>A), located in coding exon 11 of the CACNB2 gene, results from a G to A substitution at nucleotide position 1114. The alanine at codon 372 is replaced by threonine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at